WO1999024048A1 - Arzneimittel für krebs-therapie - Google Patents
Arzneimittel für krebs-therapie Download PDFInfo
- Publication number
- WO1999024048A1 WO1999024048A1 PCT/EP1997/006155 EP9706155W WO9924048A1 WO 1999024048 A1 WO1999024048 A1 WO 1999024048A1 EP 9706155 W EP9706155 W EP 9706155W WO 9924048 A1 WO9924048 A1 WO 9924048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- medicament
- drakocephalum
- kotshyi
- boss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a medicament for cancer therapy, which is based on biology.
- Cancer is a disease in which body cells grow uncontrollably.
- Various therapies are known to prevent or at least limit such cell growth.
- One of the most frequently used therapies at the moment is the so-called chemotherapy, which triggers considerable side effects, but without leading to lasting success.
- the object of the invention is a pharmaceutical or pharmaceutical
- the anti-cancer agent according to the invention is a medicament which contains two plant substances with a cytotoxic effect and which can be administered orally and / or rectally and / or parenterally.
- This combination anti-cancer preparation preferably contains extracts from two plants, namely Peganum harmala L. and Drakocephalum Kotshyi Boss, which contain anti-cancer substances. Such plants are native to Iran.
- the ingredients or contents of the plant extracts to be used according to the invention were first prepared as alcoholic and aqueous extracts or solutions. Granules are produced from the resulting mixture. The extracts and granules obtained in this way were processed into tablets and other pharmaceutical forms of administration so that they could be administered to patients.
- the drug according to the invention shows u. a. cytotoxic, anti-phlogistic, anti-inflammatory, analgesic, antibacterial and anti-viral effects.
- the biological anti-cancer agent according to the invention acts as a mitotic inhibitor and interferes with the itosis phase in the cell division of cancerous cells.
- the biological anti-cancer agent according to the invention binds to the deoxiribonucleic acid (DNA) chain after administration and thereby prevents the formation of ribonucleic acid (RNA). On this basis, it affects the amino acids of cancer-affected cells and thus prevents cancer cell growth.
- DNA deoxiribonucleic acid
- RNA ribonucleic acid
- the molecular structure of the biological anti-cancer agent or preparation according to the invention is designed so that the agent functions as a physiological and body-compatible agent in the body. It has been shown that the medicament or preparation according to the invention produces positive therapeutic effects in various cancer tumors, for example mom carcinoma, carcino e of the gastrointestinal tract, brain tumors and others.
- a particular advantage of the invention is that the positive therapeutic effect against the cancer cells is achieved without any notable side effects.
- the medicament or preparation according to the invention has no negative side effects on the blood picture and the natural blood components when administered.
- the medicament or preparation according to the invention can be administered as a mono- and / or combination therapy preparation with other biological substances and anti-tumor agents which have been produced on a biological and / or conventional basis.
- the medicament or preparation according to the invention has a synergistic effect in combination with oral oxygen therapy, whereby the anti-cancer effect is enhanced.
- the agent or preparation according to the invention has a relaxation and relaxation effect, especially with smooth muscles.
- the medicament or preparation according to the invention has immunostimulating and immunomodulating effects. These properties have been studied and confirmed in animals whose immune system has been paralyzed by diethylbenzan traces (DMBA) as a carcinogenic and immunosuppressive agent. After treatment with the biological anti-cancer agent according to the invention, an immune stimulation and immune modulation was determined and documented in these animals. These positive effects on the human immune system have also been demonstrated. A decrease in tumor markers could also be detected in cancer patients treated with the medicament or preparation according to the invention.
- DMBA diethylbenzan traces
- LD 50 lethal dose
- the cancer-inhibiting effect of the medicament or preparation according to the invention has been confirmed and documented by various cell examinations and effects on cancer cells of humans and monkeys.
- the extract obtained and produced according to the invention from two special plants and its fractions have been allowed to act on cancer cells and control cells.
- the course of this action was checked by an electronic microscope. Ultrastructural damage to the cancer cells was shown in comparison with healthy control cells.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97948892A EP0951291A1 (de) | 1997-11-06 | 1997-11-06 | Arzneimittel für krebs-therapie |
JP52524399A JP2001514671A (ja) | 1997-11-06 | 1997-11-06 | 癌治療薬 |
PCT/EP1997/006155 WO1999024048A1 (de) | 1997-11-06 | 1997-11-06 | Arzneimittel für krebs-therapie |
CA002276276A CA2276276A1 (en) | 1997-11-06 | 1997-11-06 | Cancer treatment drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1997/006155 WO1999024048A1 (de) | 1997-11-06 | 1997-11-06 | Arzneimittel für krebs-therapie |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999024048A1 true WO1999024048A1 (de) | 1999-05-20 |
Family
ID=8166782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/006155 WO1999024048A1 (de) | 1997-11-06 | 1997-11-06 | Arzneimittel für krebs-therapie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0951291A1 (de) |
JP (1) | JP2001514671A (de) |
CA (1) | CA2276276A1 (de) |
WO (1) | WO1999024048A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102286085A (zh) * | 2011-07-25 | 2011-12-21 | 新疆大学 | 一种骆驼蓬脂转移蛋白及其制备方法和应用 |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
RU2762111C1 (ru) * | 2010-08-24 | 2021-12-15 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Соединения для лечения рака |
US11465987B2 (en) | 2010-03-01 | 2022-10-11 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1034135A (zh) * | 1987-10-27 | 1989-07-26 | 新疆医学院第二附属医院 | 骆驼蓬种子浸膏的制备方法 |
CN1104507A (zh) * | 1993-11-18 | 1995-07-05 | 王世渝 | 骆驼蓬制剂及制备方法 |
-
1997
- 1997-11-06 CA CA002276276A patent/CA2276276A1/en not_active Abandoned
- 1997-11-06 WO PCT/EP1997/006155 patent/WO1999024048A1/de not_active Application Discontinuation
- 1997-11-06 EP EP97948892A patent/EP0951291A1/de not_active Withdrawn
- 1997-11-06 JP JP52524399A patent/JP2001514671A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1034135A (zh) * | 1987-10-27 | 1989-07-26 | 新疆医学院第二附属医院 | 骆驼蓬种子浸膏的制备方法 |
CN1104507A (zh) * | 1993-11-18 | 1995-07-05 | 王世渝 | 骆驼蓬制剂及制备方法 |
Non-Patent Citations (4)
Title |
---|
BIOLOGICAL ABSTRACTS, vol. 103, 1997, Philadelphia, PA, US; abstract no. 146285, CHACHOYAN A. A. ET AL.: "ANTITUMOR ACTIVITY OF SOME SPECIES OF THE FAMILY LAMIACEAE" XP002067839 * |
DATABASE WPI Section Ch Week 9024, Derwent World Patents Index; Class B04, AN 90-179297, XP002067841 * |
DATABASE WPI Section Ch Week 9729, Derwent World Patents Index; Class B04, AN 97-311153, XP002067840 * |
RASTITEL'NYE RESURSY, vol. 32, no. 4, 1996, pages 59 - 64 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
US11465987B2 (en) | 2010-03-01 | 2022-10-11 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
RU2762111C1 (ru) * | 2010-08-24 | 2021-12-15 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Соединения для лечения рака |
CN102286085A (zh) * | 2011-07-25 | 2011-12-21 | 新疆大学 | 一种骆驼蓬脂转移蛋白及其制备方法和应用 |
CN102286085B (zh) * | 2011-07-25 | 2014-06-11 | 新疆大学 | 一种骆驼蓬脂转移蛋白及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
EP0951291A1 (de) | 1999-10-27 |
JP2001514671A (ja) | 2001-09-11 |
CA2276276A1 (en) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0326034B1 (de) | Kombinationspräparat zur Behandlung von Nervenzell-und Nervenfasererkrankungen und Verletzungen | |
CH659948A5 (de) | Mittel zur verstaerkung der antitumor-wirksamkeit von mitomycin-c und doxorubicin-hydrochlorid. | |
DE2332484A1 (de) | Lutschpastillen mit verzoegerter freigabe | |
EP0505519B1 (de) | Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung | |
DE3117948C2 (de) | Tripeptide und diese Verbindungen enthaltende Arzneimittel | |
DE60125955T2 (de) | Bioaktive fraktion von eurycoma longifolia | |
EP0951291A1 (de) | Arzneimittel für krebs-therapie | |
DE60316298T2 (de) | Steigerung der bioverfügbarkeit/bioeffektivität durch cuminum cyminum und dessen extrakte und fraktionen | |
DE4024885A1 (de) | Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on | |
DE2715384C3 (de) | Arzneimittel gegen Diarrhöen | |
DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
WO2004082699A2 (de) | Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma | |
DE3707532C2 (de) | Verwendung einer Kombination von Extr. Gingko biloba oder mindestens einem Gingkolid und Acetylsalicylsäure oder DL-Lysin-mono-acetylsalicylat oder Diflunisal zur Behandlung von Verbrennungen, Verbrühungen, Strahlenschäden und Erfrierungen | |
EP1492546B1 (de) | Verwendung von pyrimidinnukleotiden zur behandlung von schaedigungen des peripheren nervensystems | |
DE3809427A1 (de) | Verwendung von samen des niem - baums zur prophylaxe und therapie viraler infektionen | |
DE3932778C2 (de) | ||
Chaube et al. | A novel ayurvedic anti diabetic medicine | |
DE102005060880A1 (de) | Spezialextrakt zur Verwendung als Antiarrhytmikum bei Herzrhythmusstörungen und zur Verbesserung der Koronarperfusion sowie dessen Herstellung | |
DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege | |
DE3825186A1 (de) | Oral verabreichbare, lektine enthaltende zubereitungen zur behandlung von metastasen | |
DE2015877A1 (de) | Arzneimittel | |
DE112015007252T5 (de) | Verfahren zur herstellung eines crassocephalum crepidioides extrakts, damithergestellter extrakt und verwendung des extrakts | |
DE4308443C2 (de) | Arzneimittel zur Behandlung von Retrovirusinfektionen | |
DE102007042009A1 (de) | Pharmazeutische Formel zur Behandlung des erworbenen menschlichen Immundefektsyndroms (AIDS) Herstellungsprozess |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97181192.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2276276 Country of ref document: CA Ref document number: 2276276 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09343338 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1999 525243 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997948892 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997948892 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997948892 Country of ref document: EP |